<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MOVANTIK- naloxegol oxalateÂ tablet, film coatedÂ </strong><br>AstraZeneca Pharmaceuticals LP<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MOVANTIK safely and effectively.  See full prescribing information for MOVANTIK.<br>MOVANTIKâ„¢ (naloxegol) tablets, for oral use<br>Initial U.S. Approval: 2014</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">MOVANTIK (naloxegol) is an opioid antagonist indicated for the treatment of opioid-induced <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (OIC) in adult patients with chronic non-cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> <a href="#ID_551398f0-51af-40f9-838e-8db895d30233">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>Discontinue maintenance laxative therapy before starting MOVANTIK; may resume laxatives if patients have OIC symptoms after taking MOVANTIK for 3 days <a href="#ID_ef7a0a8b-8692-416e-8d6d-f21a4578afc2">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Alteration in analgesic dosing regimen prior to starting MOVANTIK is not required <a href="#ID_ef7a0a8b-8692-416e-8d6d-f21a4578afc2">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>MOVANTIK has been shown to be efficacious in patients who have taken opioids for at least 4 weeks <a href="#ID_ef7a0a8b-8692-416e-8d6d-f21a4578afc2">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Take on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal <a href="#ID_ef7a0a8b-8692-416e-8d6d-f21a4578afc2">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Swallow tablets whole, do not crush or chew <a href="#ID_ef7a0a8b-8692-416e-8d6d-f21a4578afc2">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Avoid consumption of grapefruit or grapefruit juice <a href="#ID_ef7a0a8b-8692-416e-8d6d-f21a4578afc2">(2.1</a>, <a href="#_7.1_Effects_of">7.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Discontinue if treatment with the opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication is also discontinued <a href="#ID_ef7a0a8b-8692-416e-8d6d-f21a4578afc2">(2.1)</a>
</dd>
</dl>
<p class="Highlighta"><span class="Underline">Recommended dosage</span>:  </p>
<dl>
<dt>â€¢</dt>
<dd>25 mg once daily; if not tolerated, reduce to 12.5 mg once daily <a href="#ID_6ee9796e-50c5-49e2-9d72-fb7093a43b24">(2.2)</a>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (CLcr &lt; 60 mL/min):  12.5 mg once daily; increase to 25 mg once daily if tolerated and monitor for adverse reactions <a href="#ID_801915bd-0469-4d33-a27f-57d0618ef03c">(2.3</a>, <a href="#ID_d812bf9b-788e-4656-b0eb-52d058720bb8">8.6)</a>
</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Tablets:  12.5 mg and 25 mg <a href="#ID_4aca01b9-9797-4a05-9540-a524ffa1e55f">(3)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Patients with known or suspected <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span> and at increased risk of recurrent obstruction <a href="#ID_98d39d2c-8599-4be5-bdda-d1bc1024ef65">(4</a>, <a href="#ID_2cfed1eb-eecd-44df-812e-47372d3a6706">5.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) <a href="#ID_98d39d2c-8599-4be5-bdda-d1bc1024ef65">(4</a>, <a href="#_7.1_Effects_of">7.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Known serious or severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to MOVANTIK or any of its excipients <a href="#ID_98d39d2c-8599-4be5-bdda-d1bc1024ef65">(4)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforation</span></span>:  Consider the overall risk benefit in patients with known or suspected lesions of the GI tract. Monitor for severe, persistent or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; discontinue if development of symptoms <a href="#ID_2cfed1eb-eecd-44df-812e-47372d3a6706">(5.1)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Underline">Opioid withdrawal</span>:  Consider the overall risk benefit in patients with disruptions to the blood-brain barrier. Monitor for symptoms of opioid withdrawal <a href="#ID_57349abf-28c3-4d2f-937b-92fd83221031">(5.2)</a>
</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions in clinical trials (â‰¥ 3%) are: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <a href="#ID_15996a21-a638-47f7-b3d2-0dd4740c0999">(6.1)</a> </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Underline">Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil)</span>:  Increased naloxegol concentrations; avoid concomitant use; if unavoidable, reduce dosage to 12.5 mg once daily and monitor for adverse reactions <a href="#ID_68ec23c1-5804-40db-9d5a-56d2fde6ea22">(2.4</a>, <a href="#_7.1_Effects_of">7.1)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Underline">Strong CYP3A4 inducers (e.g., rifampin)</span>:  Decreased concentrations of naloxegol; concomitant use is not recommended <a href="#_7.1_Effects_of">(7.1)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Underline">Other opioid antagonists</span>:  Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use <a href="#_7.1_Effects_of">(7.1)</a>
</dd>
</dl></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Underline">Pregnancy</span>:  May precipitate opioid withdrawal in a fetus <a href="#ID_fa512eca-a7a0-4dcc-a81c-16b6eb4a9696">(8.1)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Underline">Nursing Mothers</span>:  Discontinue drug or nursing taking into consideration importance of drug to mother <a href="#ID_faa3002a-8fd0-45bc-8d2a-d2af732c8eda">(8.3)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: avoid in severe impairment <a href="#ID_bcc0301a-2113-4248-9991-e7bc3573a824">(8.7)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Administration </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Adult Dosage</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage in Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosage Recommendations due to Drug Interactions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Opioid Withdrawal</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effects of Other Drugs on MOVANTIK </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_551398f0-51af-40f9-838e-8db895d30233"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">MOVANTIK (naloxegol) is indicated for the treatment of opioid-induced <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (OIC) in adult patients with chronic non-cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_3637c573-a15d-47c6-9af4-f60be03c5c7f"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ef7a0a8b-8692-416e-8d6d-f21a4578afc2"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Administration </h2>
<dl>
<dt>â€¢</dt>
<dd>Discontinue all maintenance laxative therapy prior to initiation of MOVANTIK. Laxative(s) can be used as needed if there is a suboptimal response to MOVANTIK after three days. </dd>
<dt>â€¢</dt>
<dd>Alteration in analgesic dosing regimen prior to initiating MOVANTIK is not required. </dd>
<dt>â€¢</dt>
<dd>MOVANTIK has been shown to be efficacious in patients who have taken opioids for at least 4 weeks. Sustained exposure to opioids prior to starting MOVANTIK may increase the patient's sensitivity to the effects of MOVANTIK [<span class="Italics">see </span><span class="Italics"><a href="#ID_dd159e29-91c9-40b1-b699-5607269f8e58">Clinical Studies (14)</a></span>].</dd>
<dt>â€¢</dt>
<dd>Take MOVANTIK on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal. </dd>
<dt>â€¢</dt>
<dd>Swallow tablets whole, do not crush or chew. </dd>
<dt>â€¢</dt>
<dd>Avoid consumption of grapefruit or grapefruit juice during treatment with MOVANTIK.</dd>
<dt>â€¢</dt>
<dd>Discontinue MOVANTIK if treatment with the opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication is also discontinued.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6ee9796e-50c5-49e2-9d72-fb7093a43b24"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Adult Dosage</h2>
<p class="First">The recommended MOVANTIK dosage is 25 mg once daily in the morning. </p>
<p>If patients are not able to tolerate MOVANTIK, reduce the dosage to 12.5 mg once daily [<span class="Italics">see </span><span class="Italics"><a href="#ID_77e1fcc9-9dd2-451e-91bb-df452aed6efc">Clinical Pharmacology (12.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_801915bd-0469-4d33-a27f-57d0618ef03c"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosage in Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The starting dosage for patients with creatinine clearance (CLcr) &lt; 60 mL/min (i.e., patients with moderate, severe or end-stage <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>) is 12.5 mg once daily. If this dosage is well tolerated but OIC symptoms continue, the dosage may be increased to 25 mg once daily taking into consideration the potential for markedly increased exposures in some patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and the increased risk of adverse reactions with higher exposures [<span class="Italics">see </span><span class="Italics"><a href="#ID_d812bf9b-788e-4656-b0eb-52d058720bb8">Use in Specific Populations (8.6)</a></span> and <span class="Italics"><a href="#ID_76e45eb5-2f61-4e5b-bf51-ad0cec747417">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_68ec23c1-5804-40db-9d5a-56d2fde6ea22"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosage Recommendations due to Drug Interactions</h2>
<p class="First">Avoid concomitant use of MOVANTIK with moderate CYP3A4 inhibitor drugs (e.g., diltiazem, erythromycin, verapamil). If concurrent use is unavoidable, reduce the MOVANTIK dosage to 12.5 mg once daily and monitor for adverse reactions [<span class="Italics">see </span><span class="Italics"><a href="#_7.1_Effects_of">Drug Interactions (7.1)</a></span> and <span class="Italics"><a href="#ID_76e45eb5-2f61-4e5b-bf51-ad0cec747417">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_4aca01b9-9797-4a05-9540-a524ffa1e55f"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">MOVANTIK (naloxegol) is available in two strengths:</p>
<dl>
<dt>â€¢</dt>
<dd>Tablets:  12.5 mg supplied as mauve, oval, biconvex, film-coated, intagliated with â€œnGLâ€? on one side and â€œ12.5â€? on the other side.</dd>
<dt>â€¢</dt>
<dd>Tablets:  25 mg supplied as mauve, oval, biconvex, film-coated, intagliated with â€œnGLâ€? on one side and â€œ25â€? on the other side.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_98d39d2c-8599-4be5-bdda-d1bc1024ef65"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">MOVANTIK is contraindicated in:</p>
<dl>
<dt>â€¢</dt>
<dd>Patients with known or suspected <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span> and patients at increased risk of recurrent obstruction, due to the potential for <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> [<span class="Italics">see </span><span class="Italics"><a href="#ID_2cfed1eb-eecd-44df-812e-47372d3a6706">Warnings and Precautions (5.1)</a></span>].</dd>
<dt>â€¢</dt>
<dd>Patients concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms such as <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span> [<span class="Italics">see </span><span class="Italics"><a href="#_7.1_Effects_of">Drug Interactions (7.1)</a></span> and <span class="Italics"><a href="#ID_76e45eb5-2f61-4e5b-bf51-ad0cec747417">Pharmacokinetics (12.3)</a></span>]. </dd>
<dt>â€¢</dt>
<dd>Patients who have had a known serious or severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to MOVANTIK or any of its excipients.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_2764ac1b-0c99-4bfd-97d7-0478c761b34d"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2cfed1eb-eecd-44df-812e-47372d3a6706"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> have been reported with use of another peripherally acting opioid antagonist in patients with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the gastrointestinal tract (e.g., <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>, Ogilvieâ€™s syndrome, <span class="product-label-link" type="condition" conceptid="4150051" conceptname="Diverticulum">diverticular disease</span>, infiltrative gastrointestinal tract malignancies or peritoneal <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>). Take into account the overall risk-benefit profile when using MOVANTIK in patients with these conditions or other conditions which might result in impaired integrity of the gastrointestinal tract wall (e.g., Crohnâ€™s disease). Monitor for the development of severe, persistent or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; discontinue MOVANTIK in patients who develop this symptom [<span class="Italics">see </span><span class="Italics"><a href="#ID_98d39d2c-8599-4be5-bdda-d1bc1024ef65">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_57349abf-28c3-4d2f-937b-92fd83221031"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Opioid Withdrawal</h2>
<p class="First">Clusters of symptoms consistent with opioid withdrawal, including <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span> have occurred in patients treated with MOVANTIK [<span class="Italics">see </span><span class="Italics"><a href="#ID_15996a21-a638-47f7-b3d2-0dd4740c0999">Adverse Reactions (6.1)</a></span>]. In addition, patients receiving methadone as therapy for their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> condition were observed in clinical trials to have a higher frequency of gastrointestinal adverse reactions that may have been related to opioid withdrawal than patients receiving other opioids [<span class="Italics">see </span><span class="Italics"><a href="#ID_15996a21-a638-47f7-b3d2-0dd4740c0999">Adverse Reactions (6.1)</a></span>]. Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal or reduced <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Take into account the overall risk-benefit profile when using MOVANTIK in such patients. Monitor for symptoms of opioid withdrawal in such patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_2099bc83-2e48-4c1c-91ed-2a33c4a42bdf"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Serious and important adverse reactions described elsewhere in labeling include:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforation</span> [<span class="Italics">see  <a href="#ID_2cfed1eb-eecd-44df-812e-47372d3a6706">Warnings and Precautions (5.1)</a></span>] </dd>
<dt>â€¢</dt>
<dd>Opioid withdrawal [<span class="Italics">see </span><span class="Italics"><a href="#ID_57349abf-28c3-4d2f-937b-92fd83221031">Warnings and Precautions (5.2)</a></span>]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_15996a21-a638-47f7-b3d2-0dd4740c0999"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to MOVANTIK in 1497 patients in clinical trials, including 537 patients exposed for greater than six months, and 320 patients exposed for 12 months.</p>
<p>The safety data described in Table 1 are derived from two double-blind, placebo-controlled trials (Studies 1 and 2) in patients with OIC and non-cancer related <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> [<span class="Italics">see </span><span class="Italics"><a href="#ID_dd159e29-91c9-40b1-b699-5607269f8e58">Clinical Studies (14)</a></span>].</p>
<p>Study 3 (n=302) was a safety extension study that allowed patients from Study 1 to continue the same blinded treatment for an additional 12 weeks. Safety data for patients in Study 3 are similar to those listed in Table 1.</p>
<p>Study 4 (n=844) was a Phase 3, 52-week, multi-center, open-label, randomized, parallel group, safety and tolerability study of naloxegol versus usual care treatment for OIC (as determined by the investigator and excluding peripheral opioid antagonists) in patients with non-cancer related <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The population enrolled in Study 4 was similar to that of the other studies. Eligible patients were randomized in a 2:1 ratio to receive either naloxegol 25 mg once daily or usual care treatment for OIC. The most commonly used laxatives in the usual care group were rectal stimulants (e.g., bisacodyl), oral stimulants (e.g., senna), and oral osmotics (e.g., macrogol, magnesium). Safety data for patients in Study 4 are similar to those listed in Table 1.</p>
<p>Table 1 lists adverse reactions in pooled Studies 1 and 2 occurring in â‰¥ 3% of patients receiving MOVANTIK 12.5 mg or 25 mg and at an incidence greater than placebo.</p>
<table width="455.4pt">
<caption><span>Table 1. Adverse Reactions<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> in Patients with OIC and Non-Cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (Studies 1 and 2)</span></caption>
<col width="28%">
<col width="23%">
<col width="23%">
<col width="23%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Adverse reactions occurring in â‰¥3% of patients receiving MOVANTIK 12.5 mg or 25 mg and at an incidence greater than placebo.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd><span class="Bold">Adverse Reaction</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">MOVANTIK  25 mg</span></p>
<p><span class="Bold">(n=446)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">MOVANTIK 12.5 mg </span></p>
<p><span class="Bold">(n=441)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(n=444)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">21%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&lt;1%</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Opioid Withdrawal</span></p>
<p>Possible opioid withdrawal, defined as at least three adverse reactions potentially related to opioid withdrawal that occurred on the same day and were not all related to the gastrointestinal system, occurred in less than 1% (1/444) of placebo subjects, 1% (5/441) receiving MOVANTIK 12.5 mg, and 3% (14/446) receiving MOVANTIK 25 mg in Studies 1 and 2 regardless of maintenance opioid treatment. Symptoms included but were not limited to <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>. Patients receiving methadone as therapy for their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> condition were observed in Studies 1 and 2 to have a higher frequency of gastrointestinal adverse reactions than patients receiving other opioids [39% (7/18) vs. 26% (110/423) in the 12.5 mg group; 75% (24/32) vs. 34% (142/414) in the 25Â mg group].</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_9488e0ad-cfa1-454c-bdc4-8efe3470a246"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_61c50353-3b20-449d-8d47-b504f6935425"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effects of Other Drugs on MOVANTIK </h2>
<p class="First">Table 2 displays the effects of other drugs on MOVANTIK.</p>
<table cellpadding="0pt" width="531pt">
<caption><span>Table 2. Effects of Other Drugs on MOVANTIK</span></caption>
<col width="28%">
<col width="31%">
<col width="41%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation dependent. Studies have shown that it can be classified as a â€œstrong CYP3A inhibitorâ€? when a certain preparation was used (e.g., high dose, double strength) or as a â€œmoderate CYP3A inhibitorâ€? when another preparation was used (e.g., low dose, single strength).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Concomitant Agent</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Mechanism of Action</span></p></td>
<td class="Botrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd><span class="Bold">Clinical Recommendation</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">CYP3A4 Inhibitors</span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)</dd>
</dl></td>
<td class="Botrule Rrule" rowspan="2" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Increase plasma naloxegol concentrations and may increase the risk of adverse reactions [<span class="Italics">see  <span class="Underline"><a href="#ID_76e45eb5-2f61-4e5b-bf51-ad0cec747417">Clinical Pharmacology (12.3)</a></span></span>]<span class="Italics">.Â  </span>
</dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Use with strong CYP3A4 inhibitors is contraindicated [<span class="Italics">see <span class="Underline"><a href="#ID_98d39d2c-8599-4be5-bdda-d1bc1024ef65">Contraindications (4)</a></span></span>].</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil)</dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Avoid use with moderate CYP3A4 inhibitors; if unavoidable, decrease the dosage of MOVANTIK to 12.5 mg once daily and monitor for adverse reactions [<span class="Italics">see  <span class="Underline"><a href="#ID_68ec23c1-5804-40db-9d5a-56d2fde6ea22">Dosage and Administration (2.4)</a></span></span>].</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Weak CYP3A4 inhibitors (e.g., quinidine, cimetidine)</dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Clinically significant increases in naloxegol concentrations are not expected.  </dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>No dosage adjustments are necessary. </dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Grapefruit or grapefruit juice<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Can increase plasma naloxegol concentrations. </dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Avoid consumption of grapefruit or grapefruit juice during treatment with MOVANTIK [<span class="Italics">see  <span class="Underline"><a href="#ID_ef7a0a8b-8692-416e-8d6d-f21a4578afc2">Dosage and Administration (2.1)</a></span></span>].</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>Â </dt>
<dd><span class="Bold">CYP3A4 Inducers</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. Johnâ€™s Wort)</dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Significantly decrease plasma naloxegol concentrations and may decrease the efficacy of MOVANTIK [<span class="Italics">see  <span class="Underline"><a href="#ID_76e45eb5-2f61-4e5b-bf51-ad0cec747417">Clinical Pharmacology (12.3)</a></span></span>].Â Â Â  </dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Use with strong CYP3A4 inducers is not recommended<span class="Italics">.</span>
</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Other Drug Interactions</span></p></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Other opioid antagonists</dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Potential for additive effect of opioid receptor antagonism and increased risk of opioid withdrawal.</dd>
</dl></td>
<td class="Botrule Rrule" valign="middle"><dl>
<dt>â€¢</dt>
<dd>Avoid use of MOVANTIK<span class="Bold"></span>with another opioid antagonist.</dd>
</dl></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_3b7558a7-e62e-4a20-8e2d-f28a404e935d"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_fa512eca-a7a0-4dcc-a81c-16b6eb4a9696"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C </p>
<p><span class="Underline">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies with MOVANTIK in pregnant women. The use of MOVANTIK during pregnancy may precipitate opioid withdrawal in a fetus due to the immature fetal blood brain barrier. No effects on embryo-fetal development were observed following administration of naloxegol in pregnant rats during the period of organogenesis at doses up to 1452 times the human AUC (area under the plasma concentration-time curve) at the maximum recommended human dose. No effects on embryo-fetal development were observed following administration of naloxegol in pregnant rabbits during the period of organogenesis at doses up to 409 times the human AUC at the maximum recommended human dose. MOVANTIK should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Underline">Animal Data</span></p>
<p>Oral administration of up to 750 mg/kg/day naloxegol in rats (1452 times the human AUC at the maximum recommended human dose) and 450 mg/kg/day naloxegol in rabbits (409 times the human AUC at the maximum recommended human dose) during the period of organogenesis produced no adverse effects on embryo-fetal development. Oral administration of up to 500 mg/kg/day in rats (195 times the maximum recommended human dose based on body surface area) during the period of organogenesis through lactation produced no adverse effects on parturition or the offspring.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_faa3002a-8fd0-45bc-8d2a-d2af732c8eda"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is unknown whether MOVANTIK is present in human milk; however, naloxegol is present in rat milk and is absorbed in nursing rat pups. Because of the potential for serious adverse reactions, including opioid withdrawal, in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_f6acb937-0255-4224-8c7b-147c53fab4b8"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of MOVANTIK have not been established in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_811959b9-ad02-475e-b95f-38499fc2db56"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of MOVANTIK, 11 percent were 65 and over, while 2 percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. </p>
<p>MOVANTIK exposure was higher in elderly healthy Japanese subjects compared to young subjects [<span class="Italics">see </span><span class="Italics"><a href="#ID_76e45eb5-2f61-4e5b-bf51-ad0cec747417">Clinical Pharmacology (12.3)</a></span>]. No dosage adjustment is needed in elderly patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d812bf9b-788e-4656-b0eb-52d058720bb8"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Some subjects with creatinine clearance (CLcr) values &lt; 60 mL/minute (i.e., moderate, severe or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>) were shown to exhibit markedly higher systemic exposure of naloxegol compared to subjects with normal renal function. The reason for these high exposures is not understood. However, as the risk of adverse reactions increases with systemic exposure, a lower starting dosage of 12.5 mg once daily is recommended. No dosage adjustment is needed in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see </span><span class="Italics"><a href="#ID_801915bd-0469-4d33-a27f-57d0618ef03c">Dosage and Administration (2.3)</a></span>, and <span class="Italics"><a href="#ID_76e45eb5-2f61-4e5b-bf51-ad0cec747417">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bcc0301a-2113-4248-9991-e7bc3573a824"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) on the pharmacokinetics of naloxegol has not been evaluated. Avoid use of MOVANTIK in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, as the dosage in these patients has not been determined. No dosage adjustment is required for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see </span><span class="Italics"><a href="#ID_76e45eb5-2f61-4e5b-bf51-ad0cec747417">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_f1b0b3e9-0431-4fce-84fd-c4e1de08279a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In a clinical study of patients with OIC a daily dose of 50 mg (twice the recommended dosage), administered over 4 weeks, was associated with an increased incidence of GI adverse reactions, such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. These adverse reactions frequently occurred within 1-2 days after dosing.</p>
<p>No antidote is known for naloxegol. Dialysis was noted to be ineffective as a means of elimination in a clinical study in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. </p>
<p>If a patient on opioid therapy receives an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of naloxegol, the patient should be monitored closely for potential evidence of opioid withdrawal symptoms such as <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> or reversal of central <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span>. Base treatment on the degree of opioid withdrawal symptoms, including changes in blood pressure and heart rate, and on the need for <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_f8b0977b-052d-4cbe-8bc6-58c1496f6d36"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">MOVANTIK (naloxegol), an opioid antagonist, contains naloxegol oxalate as the active ingredient. (Naloxegol is a PEGylated derivative of naloxone.) </p>
<p>The chemical name for naloxegol oxalate is:  (5Î±,6Î±)-17-allyl-6-(2,5,8,11,14,17,20-heptaoxadocosan-22-yloxy)-4,5-epoxymorphinan-3,14-diol oxalate. The structural formula is:</p>
<div class="Figure">
<a name="id685762319"></a><img alt="Chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f49c6978-ca7b-4a66-919b-757f8f92ef64&amp;name=image-01.jpg">
</div>
<p>The empirical formula for naloxegol oxalate is C<span class="Sub">34</span>H<span class="Sub">53</span>NO<span class="Sub">11</span>.C<span class="Sub">2</span>H<span class="Sub">2</span>O<span class="Sub">4</span> and the molecular weight is 742.</p>
<p>Naloxegol oxalate is a white to off-white powder, with high aqueous solubility across the physiologic pH range.</p>
<p>MOVANTIK (naloxegol) tablets for oral use contain 14.2 mg and 28.5 mg of naloxegol oxalate, respectively equivalent to 12.5 mg and 25 mg of naloxegol.</p>
<p>Excipients in tablet core are: mannitol, cellulose microcrystalline, croscarmellose sodium, magnesium stearate, and propyl gallate. </p>
<p>Excipients in tablet coat are: hypromellose, titanium dioxide, polyethylene glycol, iron oxide red, and iron oxide black.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_59b122fa-f2c2-4faf-8598-834dce33f293"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_311a3298-e156-40c0-bd7f-3b0af44ade60"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Naloxegol is an antagonist of opioid binding at the mu-opioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids.</p>
<p>Naloxegol is a PEGylated derivative of naloxone, and is a substrate for the P-glycoprotein transporter (P-gp). Also, the presence of the PEG moiety in naloxegol reduces its passive permeability as compared with naloxone. Due to the reduced permeability and increased efflux of naloxegol across the blood-brain barrier, related to P-gp substrate properties, the CNS penetration of naloxegol is expected to be negligible at the recommended dose levels limiting the potential for interference with centrally mediated opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_77e1fcc9-9dd2-451e-91bb-df452aed6efc"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Use of opioids induces slowing of gastrointestinal motility and transit. Antagonism of gastrointestinal mu-opioid receptors by naloxegol inhibits opioid-induced delay of gastrointestinal transit time. </p>
<p><span class="Underline">Effect on Cardiac Repolarization </span></p>
<p>In a randomized, double-blind, 4-way cross-over thorough QTc prolongation study with moxifloxacin as a positive control, a single 25 mg therapeutic dose or a 150 mg dose (6 times the maximum recommended dosage) of naloxegol, did not have an effect on the QTc interval compared to placebo. Changes in heart rate, RR, PR, and QRS ECG intervals were similar between placebo and naloxegol 25 or 150 mg.</p>
<p><span class="Underline">Exposure Response Analysis</span></p>
<p>The exposure-response analysis for adverse events showed that the probability of experiencing <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> increased with increasing naloxegol exposure over the dose range of 12.5 mg to 25 mg once a day. The exposure-response analysis for efficacy conducted using the definition of response in the clinical trials [<span class="Italics">see </span><a href="#ID_dd159e29-91c9-40b1-b699-5607269f8e58">Clinical Studies (14)</a>] indicated that response was similar over this dose range.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_76e45eb5-2f61-4e5b-bf51-ad0cec747417"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Following oral administration, MOVANTIK is absorbed with peak concentrations (C<span class="Sub">max</span>) achieved at less than 2 hours. In a majority of subjects, a secondary plasma concentration peak of naloxegol was observed approximately 0.4 to 3 hours after the first peak. Across the range of doses evaluated, peak plasma concentration and area under the plasma concentration-time curve (AUC) increased in a dose-proportional or almost dose-proportional manner. Accumulation was minimal following multiple daily doses of naloxegol. </p>
<p><span class="Underline">Food Effects </span></p>
<p>A high-fat meal increased the extent and rate of naloxegol absorption. The C<span class="Sub">max </span>and AUC were increased by approximately 30% and 45%, respectively. In clinical trials, naloxegol was dosed on an empty stomach approximately 1 hour prior to the first meal in the morning.</p>
<p><span class="Underline">Distribution</span></p>
<p>The mean apparent volume of distribution during the terminal phase (Vz/F) in healthy volunteers ranged from 968 L to 2140 L across dosing groups and studies. Plasma protein binding of naloxegol in humans was low (~4.2 %).</p>
<p><span class="Underline">Metabolism</span></p>
<p>Naloxegol is metabolized primarily by the CYP3A enzyme system. In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study in humans, a total of 6 metabolites were identified in plasma, urine and feces. These metabolites were formed via N-dealkylation, O-demethylation, oxidation and partial loss of the PEG chain. Human metabolism data suggests absence of major metabolites. The activity of the metabolites at the opioid receptor has not been determined.</p>
<p><span class="Underline">Excretion</span></p>
<p>Following oral administration of radio-labelled naloxegol, 68% and 16% of total administered dose were recovered in the feces and urine, respectively. Parent naloxegol excreted in the urine accounted for less than 6% of the total administered dose. Approximately 16% of radioactivity in feces was noted to be unchanged naloxegol, while the remaining was attributed to metabolites. Thus, renal excretion is a minor clearance pathway for naloxegol. In a clinical pharmacology study, the half-life of naloxegol at therapeutic doses ranged from 6 to 11 hours.</p>
<p><span class="Underline">Specific Populations</span></p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>:</span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of a 25 mg single oral dose of MOVANTIK was studied in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (RI) classified as moderate (n=8), severe (n=4), or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) not yet on dialysis (n=4), and compared with healthy subjects (n=6). Most <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (RI) subjects (6 out of 8 with moderate RI, 3 out of 4 with severe RI, and 3 out of 4 with ESRD) had plasma naloxegol pharmacokinetics comparable to those in healthy subjects. The remaining individuals with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> demonstrated higher naloxegol exposures (up to 10-fold) compared to the control group. The reason for these high exposures is unknown.</p>
<p>This study also included 8 ESRD patients on hemodialysis. Plasma concentrations of naloxegol in these subjects were similar to healthy volunteers with normal renal function, when MOVANTIK was administered either pre- or post-</p>
<p>hemodialysis [<span class="Italics">see </span><span class="Italics"><a href="#ID_801915bd-0469-4d33-a27f-57d0618ef03c">Dosage and Administration (2.3)</a></span>, <span class="Italics"><a href="#ID_d812bf9b-788e-4656-b0eb-52d058720bb8">Use in Specific Populations (8.6)</a></span>, and <span class="Italics"><a href="#ID_f1b0b3e9-0431-4fce-84fd-c4e1de08279a">Overdosage (10)</a></span>].</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>:</span></p>
<p>Slight decreases in AUC of naloxegol were observed in subjects with mild and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Classes A and B; n = 8 per group) compared to subjects with normal hepatic function (n = 8), following administration of a single 25 mg oral dose of MOVANTIK. The effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) on the pharmacokinetics of naloxegol was not evaluated [<span class="Italics">see </span><span class="Italics"><a href="#ID_bcc0301a-2113-4248-9991-e7bc3573a824">Use in Specific Populations (8.7)</a></span>].</p>
<p><span class="Italics"><span class="Underline">Age</span>:</span></p>
<p>The mean C<span class="Sub">max</span>,<span class="Sub">ss</span> and AUC<span class="Sub">Ï„,ss</span> values seen in elderly healthy Japanese subjects (n = 6) were approximately 45% and 54% greater than those obtained in young healthy subjects (n = 6) following multiple daily doses of naloxegol (25 mg). </p>
<p><span class="Italics"><span class="Underline">Gender</span>:</span></p>
<p>There is no gender effect on the pharmacokinetics of naloxegol. </p>
<p><span class="Italics"><span class="Underline">Race</span>:</span></p>
<p>In clinical trials, Caucasian subjects exhibited approximately 20% higher naloxegol AUC when compared to other races. </p>
<p><span class="Underline">Drug Interaction Studies</span></p>
<p><span class="Italics"><span class="Underline">Effect of MOVANTIK on Other Drugs</span></span></p>
<p>In <span class="Italics">in vitro</span> studies at clinically relevant concentrations, naloxegol did not show a significant inhibitory effect on the activity of CYP1A2, CYP2C9, CYP2D6, CYP3A4 or CYP2C19, nor a significant induction effect on the activity of CYP1A2, CYP2B6 or CYP3A4. Therefore, MOVANTIK is not expected to alter the metabolic clearance of co-administered drugs that are metabolized by these enzymes. Naloxegol is not a significant inhibitor of P-gp, BCRP, OAT1, OAT3, OCT2, OATP1B1 and OATP1B3. </p>
<p>In healthy subjects receiving morphine 5 mg/70 kg intravenously, single doses of MOVANTIK ranging from 8 mg to 1000 mg were given concomitantly with 5 to 6 subjects per dose cohort. With increasing MOVANTIK dose, there was no increasing or decreasing trend in morphine exposure compared to morphine administered alone. An analysis of the pooled data indicated that MOVANTIK had no meaningful impact on the systemic exposure of morphine and its major circulating metabolites.</p>
<p><span class="Italics"><span class="Underline">Effect of Other Drugs on MOVANTIK</span></span></p>
<p>Naloxegol is metabolized mainly by CYP3A enzymes and is a substrate of P-gp transporter. The effects of co-administered drugs on the pharmacokinetics of naloxegol are summarized in Figure 1 [<span class="Italics">see </span><span class="Italics"><a href="#_7.1_Effects_of">Drug Interactions (7.1)</a></span>].</p>
<p>The effects of once daily oral dosing of 400 mg ketoconazole, once daily oral dosing of 600 mg rifampicin and once daily oral dosing of 240 mg diltiazem (as an extended release formulation) on the pharmacokinetics of 25 mg MOVANTIK were studied following multiple dosing and at steady state exposure of the perpetrator drugs. The effects of 600 mg oral dosing of quinidine and intravenous morphine (5 mg/70 kg) on the pharmacokinetics of 25 mg MOVANTIK were studied following single dosing of the perpetrator drugs.</p>
<p><span class="Bold">Figure 1:  Effect of Co-administered Drugs on the Pharmacokinetics of Naloxegol</span><a name="id788912610"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f49c6978-ca7b-4a66-919b-757f8f92ef64&amp;name=image-02.jpg"></p>
<p>*Quinidine due to its effect on P-gp transporter increased naloxegol C<span class="Sub">max</span> by 2.5-fold; the AUC increased by 1.4-fold; no dosage adjustment is necessary.</p>
<p>No drug interaction studies have been conducted for MOVANTIK with drugs that alter gastric pH (e.g., antacids, proton-pump inhibitors). </p>
<p>Simulations using physiologically based pharmacokinetic modeling, suggested that naloxegol exposures after co-administration of a single oral 25 mg dose of MOVANTIK with a moderate CYP3A inducer efavirenz (400 mg once a day) are similar to those after 12.5 mg MOVANTIK alone. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_34edb0b4-d13c-4a53-a874-0ce5b1b09840"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_1d52f8b3-173c-4062-a84a-b9b645dbf8ab"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>In a 104-week carcinogenicity study in CD-1 mice, naloxegol was not tumorigenic at oral doses up to 100 mg/kg/day in males and 160 mg/kg/day in females (43 and 27 times the human AUC at the maximum recommended human dose for male and female mice, respectively). In a carcinogenicity study in Sprague-Dawley rats, naloxegol was administered orally at doses of 40, 120, and 400 mg/kg/day for at least 93 weeks. Naloxegol did not cause an increase in tumors in female rats. In male rats, an increase in interstitial (Leydig) cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in testes was observed at 400 mg/kg/day (818 times the human AUC at the maximum recommended human dose). The no observed effect level for increased tumor incidence was 120 mg/kg/day in male and 400 mg/kg/day in female rats (246 and 1030 times the human AUC at the maximum recommended human dose for male and female rats, respectively). The Leydig cell neoplasms in rats are considered to be unlikely relevant to humans.</p>
<p><span class="Underline">Mutagenesis</span></p>
<p>Naloxegol was not genotoxic in the <span class="Italics">in vitro</span> bacterial reverse mutation (Ames) assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> TK<span class="Sup">+/-</span> mutation assay, or the <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
<p><span class="Underline">Impairment of Fertility</span></p>
<p>Naloxegol was found to have no effect on fertility or reproductive performance in male and female rats at oral doses up to 1000 mg/kg/day (greater than 1000 times the human AUC at the maximum recommended human dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_dd159e29-91c9-40b1-b699-5607269f8e58"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of MOVANTIK was evaluated in two replicate, randomized, double-blind placebo-controlled trials (Study 1 and Study 2) in patients with opioid-induced <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (OIC) and non-cancer related <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </p>
<p>Patients receiving an opioid morphine equivalent daily dose of between 30 mg and 1,000 mg for at least four weeks before enrollment and self-reported OIC were eligible to participate. OIC was confirmed through a two-week run in period and was defined as &lt;3 spontaneous bowel movements (SBMs) per week on average with at least 25% of the SBMs associated with one or more of the following conditions:  (1) straining, (2) hard or lumpy stools; and (3) having a sensation of incomplete evacuation. An SBM was defined as a bowel movement (BM) without rescue laxative taken within the past 24 hours. Patients with 0 BMs over the two-week run-in period or patients with an uneven distribution of SBMs across the two-week run-in period (0 SBMs in one week with â‰¥4 SBMs in the other week) were excluded. Throughout the studies (including the two-week run-in period), patients were prohibited from using laxatives other than bisacodyl rescue laxative (if they had not had a BM for 72 hours) and one-time use of an enema (if after 3 doses of bisacodyl, they still did not have a BM). </p>
<p>Patients suspected of having clinically important disruptions to the blood-brain barrier were not enrolled in these studies. </p>
<p>A total of 652 patients in Study 1 and 700 patients in Study 2 were randomized in a 1:1:1 ratio to receive 12.5 mg or 25 mg of MOVANTIK or placebo once daily for 12 weeks. </p>
<p>The mean age of the subjects in these two studies was 52 years, 10% and 13% were 65 years of age or older, 61% and 63% were women, and 78% and 80% were white in Studies 1 and 2, respectively. </p>
<p><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> was the most common reason for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (56% and 57%); <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> (10% and 10%) and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> (3% and 5%) were other prominent reasons in Studies 1 and 2, respectively. Prior to enrollment, patients had been using their current opioid for an average of 3.6 and 3.7 years. The patients who participated in Studies 1 and 2 were taking a wide range of opioids. The mean baseline opioid morphine equivalent daily dosage was 140 mg and 136 mg per day.</p>
<p>Use of one or more laxatives on at least one occasion within the two weeks prior to enrollment was reported by 71% of patients in both Studies 1 and 2. </p>
<p>The primary endpoint was response defined as:  â‰¥3 SBMs per week and a change from baseline of â‰¥1 SBM per week for at least 9 out of the 12 study weeks and 3 out of the last 4 weeks.</p>
<p>There was a statistically significant difference for the 25 mg MOVANTIK treatment group versus placebo for the primary endpoint in Study 1 and Study 2 (see Table 3). Statistical significance for the 12.5 mg treatment group versus placebo was observed in Study 1 but not in Study 2 (see Table 3).</p>
<table width="90.68%">
<caption><span>Table 3. Primary Endpoint:  Response<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> (Studies 1 and 2)</span></caption>
<col width="49%">
<col width="15%">
<col width="19%">
<col width="18%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="middle"></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">StudyÂ 1</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="middle"></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Placebo<br>(N = 214)</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="middle">12.5 mg<br>(N = 213)</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="middle">25 mg<br>(N = 214)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Response defined as: â‰¥3 SBMs per week and change from baseline of â‰¥1 SBM per week for at least 9 out of the 12 study weeks and 3 out of the last 4 weeks.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">â€ </a></dt>
<dd>Statistically significant:  p-values based on the Cochran-Mantel-Haenszel test.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Patients responding, n (%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">63 (29%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">87 (41%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">95 (44%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Treatment Difference (MOVANTIK-Placebo)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">--</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11.4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">15.0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">95% Confidence Interval</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">--</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> (2.4%, 20.4%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> (5.9%, 24.0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">p-value</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">--</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.015<a name="footnote-reference-4" href="#footnote-4" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.001<a href="#footnote-4" class="Sup">â€ </a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold">StudyÂ 2</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Placebo<br>(N = 232)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12.5 mg<br>(N = 232)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">25 mg<br>(N = 232)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Patients responding, n (%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">68 (29%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">81 (35%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">92 (40%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Treatment Difference (MOVANTIK-Placebo)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">--</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5.6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10.3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">95% Confidence Interval</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">--</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> (-2.9%, 14.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"> (1.7%, 18.9%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">p-value</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">--</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.202</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.021<a href="#footnote-4" class="Sup">â€ </a></p></td>
</tr>
</tbody>
</table>
<p>One secondary endpoint in Study 1 and Study 2 was response in laxative users with OIC symptoms. This subgroup comprised 55% and 53% of total patients in these two studies respectively. These patients (identified using an investigator-administered questionnaire), prior to enrollment, had reported using laxative(s) at least 4 out of the past 14 days with at least one of the following OIC symptoms of moderate, severe or very severe intensity:  incomplete bowel movements, hard stool, straining, or sensation of needing to pass a bowel movement but unable to do so. In this subgroup, in Studies 1 and 2, 42% and 50% reported using laxatives on a daily basis. The most frequently reported laxatives used on a daily basis were stool softeners (18% and 24%), stimulants (16% and 18%), and polyethylene glycol (6% and 5%). Use of two laxative classes was reported in 31% and 27% anytime during the 14 days prior to enrollment. The most commonly reported combination was stimulants and stool softeners (10% and 8%). In Study 1, a statistically significantly higher percentage of patients in this subgroup responded with MOVANTIK 12.5 mg compared to placebo (43% vs. 29%; p=0.03) and with MOVANTIK 25 mg compared to placebo (49% vs. 29%; p=0.002). In Study 2, a statistically significantly higher percentage of patients in this subgroup responded with MOVANTIK 25 mg compared to placebo (47% vs. 31%; p=0.01). This secondary endpoint was not tested for MOVANTIK 12.5 mg versus placebo in Study 2 because the primary endpoint was not statistically significant.</p>
<p>Another secondary endpoint was time to first post-dose SBM. The time to first post-dose SBM was significantly shorter with MOVANTIK 25 mg compared to placebo in both Study 1 (p &lt;0.001) and Study 2 (p &lt;0.001), and for MOVANTIK 12.5 mg as compared to placebo in Study 1 (p &lt;0.001). For Study 1, the median times to first post-dose SBM were 6, 20, and 36 hours with MOVANTIK 25 mg, MOVANTIK 12.5 mg, and placebo, respectively. For Study 2, the median times to first post-dose SBM were 12 and 37 hours with MOVANTIK 25 mg and placebo, respectively. These analyses do not include the results for MOVANTIK 12.5 mg versus placebo in Study 2 because the primary endpoint was not statistically significant. In the two studies, 61-70% and 58% of patients receiving MOVANTIK 25 mg and MOVANTIK 12.5 mg, respectively, had an SBM within 24 hours of the first dose.</p>
<p>A third secondary endpoint was an evaluation of change from baseline between the treatment groups for mean number of days per week with at least 1 SBM but no more than 3 SBM's. There was a significant difference in number of days per week with 1 to 3 SBMâ€™s per day on average over 12 weeks between MOVANTIK 25 mg (Study 1 and Study 2) and MOVANTIK 12.5 mg (Study 1) and placebo.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_302f8ca7-b6d5-41af-a789-09deb1f7fcd2"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">MOVANTIK (naloxegol) tablets are supplied as:</p>
<dl>
<dt>â€¢</dt>
<dd>NDC 0310-1969-30: 12.5 mg, bottle of 30 tablets</dd>
<dt>â€¢</dt>
<dd>NDC 0310-1969-90: 12.5 mg, bottle of 90 tablets</dd>
<dt>â€¢</dt>
<dd>NDC 0310-1969-39: 12.5 mg, unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> carton of 100 tablets (for HUD only)</dd>
<dt>â€¢</dt>
<dd>NDC 0310-1970-30: 25 mg, bottle of 30 tablets</dd>
<dt>â€¢</dt>
<dd>NDC 0310-1970-90: 25 mg, bottle of 90 tablets</dd>
<dt>â€¢</dt>
<dd>NDC 0310-1970-39: 25 mg, unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> carton of 100 tablets (for HUD only)</dd>
</dl>
<p><span class="Bold">Storage</span></p>
<p>Store MOVANTIK at 20-25Â°C (68-77Â°F). Excursions permitted to 15-30Â°C (59-86Â°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_d19a1e1d-fc19-4070-8196-7b84507b3867"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Medication Guide).</p>
<p><span class="Underline">Administration</span></p>
<p>Advise patients to:</p>
<dl>
<dt>â€¢</dt>
<dd>Discontinue all maintenance laxative therapy prior to initiation of MOVANTIK. Laxative(s) can be used as needed if there is a suboptimal response to MOVANTIK after three days. </dd>
<dt>â€¢</dt>
<dd>Take MOVANTIK on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal. </dd>
<dt>â€¢</dt>
<dd>Swallow tablets whole, do not crush or chew. </dd>
<dt>â€¢</dt>
<dd>Discontinue MOVANTIK if treatment with the opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication is also discontinued.</dd>
<dt>â€¢</dt>
<dd>Avoid consumption of grapefruit or grapefruit juice during treatment with MOVANTIK.</dd>
<dt>â€¢</dt>
<dd>Inform their healthcare provider if their opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication is discontinued.</dd>
<dt>â€¢</dt>
<dd>Inform their healthcare provider if they are unable to tolerate MOVANTIK, so a dosage adjustment can be considered.</dd>
</dl>
<p><span class="Underline">Drug Interactions</span></p>
<p>Advise patients to tell their healthcare provider when they start or stop taking any concomitant medications. Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) are contraindicated with MOVANTIK, and other CYP3A4 enzyme modulating drugs can alter MOVANTIK exposure [s<span class="Italics">ee </span><span class="Italics"><a href="#ID_98d39d2c-8599-4be5-bdda-d1bc1024ef65">Contraindications (4)</a></span> and <span class="Italics"><a href="#_7.1_Effects_of">Drug Interactions (7.1)</a></span>]. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></span></p>
<p>Advise patients to discontinue MOVANTIK and to promptly seek medical attention if they develop unusually severe, persistent or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
<p><span class="Underline">Opioid Withdrawal</span></p>
<p>Advise patients that clusters of symptoms consistent with opioid withdrawal may occur while taking MOVANTIK, including <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>. Inform patients taking methadone as therapy for their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> condition that they may be more likely to have gastrointestinal adverse reactions such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that may be related to opioid withdrawal, than patients receiving other opioids. </p>
<p><span class="Underline">Pregnancy</span></p>
<p>Advise females of reproductive potential, who become pregnant or are planning to become pregnant that the use of MOVANTIK during pregnancy may precipitate opioid withdrawal in a fetus due to the undeveloped blood brain barrier. </p>
<p><span class="Underline">Nursing</span></p>
<p>Advise females who are nursing against breastfeeding during treatment with MOVANTIK due to the potential for opioid withdrawal in nursing infants. </p>
<p>MOVANTIK is a trademark of the AstraZeneca group of companies.</p>
<p>Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850 </p>
<p>Â© AstraZeneca 2014</p>
<p>Revised 01/2015</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_17fba467-32ca-48cf-b804-94a71aa369fe"></a><a name="section-16"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<table width="100%">
<col width="100%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Bold">MOVANTIKâ„¢ (mo van tic)</span></p>
<p><span class="Bold">(naloxegol) tablets</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule"><p class="First">Read this Medication Guide before you start taking MOVANTIK and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p></td></tr>
<tr><td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">What is the most important information I should know about MOVANTIK? </span></p>
<p><span class="Bold">MOVANTIK may cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Tear in your stomach or intestinal wall (perforation). </span><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Stomach pain</span> that is severe can be a sign of a serious medical condition. If you get <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> that does not go away, stop taking MOVANTIK and get emergency medical help right away. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Opioid withdrawal. </span>You may have symptoms of opioid withdrawal during treatment with MOVANTIK including <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>. If you take methadone to treat your <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, you may be more likely to have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> than people who do not take methadone. Tell your health care provider if you have any of these symptoms.<span class="Bold"></span>
</dd>
</dl>
</td></tr>
<tr><td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">What is MOVANTIK? </span></p>
<p>MOVANTIK is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> that is caused by prescription <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines called opioids, in adults with long-lasting (chronic) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that is not caused by cancer. </p>
<p>It is not known if MOVANTIK is safe and effective in children. </p>
</td></tr>
<tr><td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">Who should not take MOVANTIK? </span></p>
<p><span class="Bold">Do not take MOVANTIK if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have a bowel blockage (<span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>) or have a history of bowel blockage.</dd>
<dt>â€¢</dt>
<dd>are allergic to MOVANTIK or any of the ingredients in MOVANTIK. See the end of this leaflet for a complete list of ingredients in MOVANTIK.</dd>
</dl>
<p>MOVANTIK can interact with certain other medicines and cause side effects, including opioid withdrawal symptoms such as <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>. Tell your healthcare provider or pharmacist before you start or stop any medicines during treatment with MOVANTIK.</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">What should I tell my healthcare provider before taking MOVANTIK?</span></p>
<p>Before you take MOVANTIK, tell your healthcare provider about all of your medical conditions, including if you:</p>
<dl>
<dt>â€¢</dt>
<dd>have any stomach or bowel (intestines) problems, including <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span>, Crohnâ€™s disease, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, cancer of the stomach or bowel, or Ogilvieâ€™s syndrome.</dd>
<dt>â€¢</dt>
<dd>have kidney problems. </dd>
<dt>â€¢</dt>
<dd>have liver problems.</dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. Taking MOVANTIK during pregnancy may cause opioid withdrawal symptoms in your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with MOVANTIK. </dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if MOVANTIK passes into your breast milk. </dd>
<dt>â€¢</dt>
<dd>Taking MOVANTIK while you are breastfeeding may cause opioid withdrawal in your baby. You and your healthcare provider should decide if you will take MOVANTIK or breastfeed. You should not do both. </dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all of the medicines you take</span>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Other medicines may affect the way MOVANTIK works.</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">How should I take MOVANTIK? </span></p>
<dl>
<dt>â€¢</dt>
<dd>Take MOVANTIK exactly as your healthcare provider tells you. </dd>
<dt>â€¢</dt>
<dd>Take your prescribed dose of MOVANTIK one time each day, on an empty stomach, at least 1 hour before your first meal of the day or 2 hours after the meal. </dd>
<dt>â€¢</dt>
<dd>Swallow MOVANTIK tablets whole. Do not crush or chew the tablet. </dd>
<dt>â€¢</dt>
<dd>Stop taking other laxatives before you start treatment with MOVANTIK. Your healthcare provider may prescribe other laxatives if MOVANTIK does not work after 3 days of treatment.</dd>
<dt>â€¢</dt>
<dd>MOVANTIK has been shown to be effective in people who have taken opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines for at least 4 weeks.</dd>
<dt>â€¢</dt>
<dd>Tell your healthcare provider if you stop taking your opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine. If you stop taking your opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine, you should also stop taking MOVANTIK.</dd>
<dt>â€¢</dt>
<dd>If you take too much MOVANTIK, call your healthcare provider or go to the nearest emergency room right away.</dd>
</dl>
</td></tr>
<tr><td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">What should I avoid while taking MOVANTIK?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Avoid eating grapefruit or drinking grapefruit juice during treatment with MOVANTIK.</dd>
</dl>
</td></tr>
<tr><td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">What are the possible side effects of MOVANTIK? </span></p>
<p>See <span class="Bold">â€œWhat is the most important information I should know about MOVANTIK?â€?</span></p>
<p><span class="Bold">The most common side effects of MOVANTIK include: </span>stomach (abdomen) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, gas, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not<span class="Bold"></span>all the possible side effects of MOVANTIK. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">How should I store MOVANTIK?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store MOVANTIK at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C). </dd>
<dt>â€¢</dt>
<dd>Safely throw away medicine that is out of date or that you no longer need.</dd>
</dl>
<p><span class="Bold">Keep MOVANTIK and all medicines out of the reach of children.</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">General information about MOVANTIK</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use MOVANTIK for a condition for which it was not prescribed. Do not give MOVANTIK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about MOVANTIK that is written for health professionals.</p>
</td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Bold">What are the ingredients in MOVANTIK?</span></p>
<p><span class="Bold">Active ingredient: </span>naloxegol oxalate</p>
<p><span class="Bold">Inactive ingredients: </span>The tablet core contains mannitol, cellulose microcrystalline, croscarmellose sodium, magnesium stearate, and propyl gallate. The tablet coat contains hypromellose, titanium dioxide, polyethylene glycol, iron oxide red, and iron oxide black.<span class="Bold"></span></p>
</td></tr>
</tbody>
</table>
<p class="First"></p>
<p>Distributed by:  AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850</p>
<p>MOVANTIK is a trademark of the AstraZeneca Group of companies.</p>
<p>Â© 2014 AstraZeneca Pharmaceuticals LP.  All rights reserved.  For more information, go to www.MOVANTIK.com or call 1-800-236-9933.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.                Issued: January 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_923ce02f-756a-4fb5-b392-d15d8898c4a8"></a><a name="section-17"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL â€“ 12.5</h1>
<p class="First">NDC 0310-1969-30</p>
<p>30 Tablets</p>
<p>movantikâ„¢</p>
<p>(naloxegol) Tablets</p>
<p>12.5 mg*</p>
<p>*Each tablet contains 14.2 mg naloxegol oxalate</p>
<p><span class="Bold">Dispense the accompanying Medication Guide to each patient. </span></p>
<p><span class="Bold">Rx only</span></p>
<p>AstraZeneca</p>
<div class="Figure">
<a name="id1379284438"></a><img alt="naloxegol 12.5 mg bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f49c6978-ca7b-4a66-919b-757f8f92ef64&amp;name=image-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_78503bdf-78d4-48a6-b808-89597a28bc2a"></a><a name="section-18"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL â€“ 25 mg</h1>
<p class="First">NDC 0310-1970-30</p>
<p>90 Tablets</p>
<p>movantikâ„¢</p>
<p>(naloxegol) Tablets</p>
<p>25 mg*</p>
<p>*Each tablet contains 28.5 mg naloxegol oxalate</p>
<p><span class="Bold">Dispense the accompanying Medication Guide to each patient. </span></p>
<p><span class="Bold">Rx only</span></p>
<p>AstraZeneca</p>
<div class="Figure">
<a name="id1379283663"></a><img alt="movantik 25 mg bottle, 30 tablets label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f49c6978-ca7b-4a66-919b-757f8f92ef64&amp;name=image-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOVANTIKÂ 		
					</strong><br><span class="contentTableReg">naloxegol oxalate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-1969</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NALOXEGOL OXALATE</strong> (NALOXEGOL) </td>
<td class="formItem">NALOXEGOL OXALATE</td>
<td class="formItem">12.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYL GALLATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (mauve) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">nGL;12;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-1969-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">03/06/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0310-1969-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">03/06/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0310-1969-39</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">03/06/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204760</td>
<td class="formItem">03/06/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOVANTIKÂ 		
					</strong><br><span class="contentTableReg">naloxegol oxalate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-1970</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NALOXEGOL OXALATE</strong> (NALOXEGOL) </td>
<td class="formItem">NALOXEGOL OXALATE</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYL GALLATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (mauve) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">nGL;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-1970-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">03/06/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0310-1970-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">03/06/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0310-1970-39</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem">03/06/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0310-1970-95</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem">03/06/2015</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204760</td>
<td class="formItem">03/06/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>AstraZeneca Pharmaceuticals LP
							(054743190)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>AstraZeneca PLC (230790719)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0ba46ac6-266a-44f5-901e-9ad6a1cfe00a</div>
<div>Set id: f49c6978-ca7b-4a66-919b-757f8f92ef64</div>
<div>Version: 5</div>
<div>Effective Time: 20150106</div>
</div>
</div>Â <div class="DistributorName">AstraZeneca Pharmaceuticals LP</div></p>
</body></html>
